<DOC>
	<DOCNO>NCT02708667</DOCNO>
	<brief_summary>Crizotinib , inhibitor anaplastic lymphoma kinase ( ALK ) , approve Food Drug Administration ( FDA ) treatment patient ALK-positive non-small cell lung cancer ( NSCLC ) administration achieve considerable success . However , adverse effect inevitably occur common one hepatic toxicity , appear elevate alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) . Therefore , investigator try figure mechanism crizotinib-inducing hepatic toxicity , explore whether biological marker diagnose side effect early stage , may realize individualized therapy efficacy less side effect .</brief_summary>
	<brief_title>An Observational Research Of Crizotinib 's Hepatic Toxicity In Non-small Cell Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>1. patient histologically cytologically confirm NSCLC stage III IV 2. harbor ALK fusion gene take crizotinib 3. age:18~75years 4 . Eastern cooperative oncology group performance status ( ECOG PS ) : 0~2 point 5. expect lifetime 12 week recruit 1. patient also suffer malignant tumor 2. uncontrolled systemic disease , central nervous system ( CNS ) metastasis 3. clinically active interstitial lung diseases 4. severe liver dysfunction cause hepatic cirrhosis hepatitis （ChildPugh class C , total index score 1015 points） 5. take drug interact crizotinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>crizotinib</keyword>
	<keyword>hepatic toxicity</keyword>
</DOC>